| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2017.05.070 |
| P698 | PubMed publication ID | 28596090 |
| P50 | author | Christopher J Genito | Q60045312 |
| Timothy W Phares | Q117769739 | ||
| P2093 | author name string | Norman C Waters | |
| Noelle B Patterson | |||
| Sheetij Dutta | |||
| Carl R Alving | |||
| Elke S Bergmann-Leitner | |||
| Gary R Matyas | |||
| Zoltan Beck | |||
| Fanta Kalle | |||
| Keith J Limbach | |||
| Maureen E Stefaniak | |||
| P2860 | cites work | Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP) | Q21034050 |
| TLR signaling pathways | Q24570127 | ||
| Beyond empiricism: informing vaccine development through innate immunity research | Q26824573 | ||
| A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants | Q28278852 | ||
| Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites | Q28541281 | ||
| Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults | Q28744149 | ||
| Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity | Q30039112 | ||
| Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint | Q34036184 | ||
| Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial | Q34043843 | ||
| IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice | Q34400813 | ||
| Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. | Q34401225 | ||
| Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study | Q34530710 | ||
| Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. | Q48037206 | ||
| Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. | Q53667782 | ||
| Oil-in-water liposomal emulsions for vaccine delivery | Q75234093 | ||
| The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host | Q34577701 | ||
| SPICE: exploration and analysis of post-cytometric complex multivariate datasets | Q34769778 | ||
| Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection | Q34990090 | ||
| Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. | Q35079832 | ||
| P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections | Q35561160 | ||
| Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses | Q35841913 | ||
| A Sporozoite- and Liver Stage-expressed Tryptophan-rich Protein Plays an Auxiliary Role in Plasmodium Liver Stage Development and Is a Potential Vaccine Candidate | Q35925784 | ||
| A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria | Q35927866 | ||
| Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies | Q36024455 | ||
| Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains | Q36053524 | ||
| Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex | Q36434929 | ||
| Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants | Q36466129 | ||
| Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine | Q36603519 | ||
| Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mi | Q36646698 | ||
| Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy | Q36773737 | ||
| Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine | Q36884670 | ||
| Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. | Q36983584 | ||
| Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children | Q37130595 | ||
| Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. | Q37161928 | ||
| Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates | Q37170062 | ||
| Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines | Q37361903 | ||
| Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes | Q37696415 | ||
| Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older | Q39392164 | ||
| AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity | Q39782280 | ||
| Controlled human malaria infection | Q40205689 | ||
| The Economics of Malaria Vaccine Development | Q40341968 | ||
| Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children | Q40551098 | ||
| Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. | Q40998278 | ||
| Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults | Q42145566 | ||
| Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial | Q42754531 | ||
| Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen | Q43853058 | ||
| Public health challenges and prospects for malaria control and elimination | Q43881419 | ||
| A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group | Q44174498 | ||
| Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines | Q44542837 | ||
| The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity | Q44888648 | ||
| Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations | Q45308673 | ||
| Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice | Q45359726 | ||
| First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children | Q46182948 | ||
| A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant | Q46423309 | ||
| Activity of human volunteer sera to candidate Plasmodium falciparum circumsporozoite protein vaccines in the inhibition of sporozoite invasion assay of human hepatoma cells and hepatocytes. | Q47879434 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| malaria vaccine | Q6741353 | ||
| P304 | page(s) | 3865-3874 | |
| P577 | publication date | 2017-06-05 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. | |
| P478 | volume | 35 |
| Q92960215 | A Convenient Synthetic Method to Improve Immunogenicity of Mycobacterium tuberculosis Related T-Cell Epitope Peptides |
| Q57295566 | A malaria vaccine adjuvant based on recombinant antigen binding to liposomes |
| Q64076203 | Enhanced Immunogenicity and Protective Efficacy of a Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 |
| Q93056756 | Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate |
| Q59799358 | Identification of Immune Signatures of Novel Adjuvant Formulations Using Machine Learning |
| Q50060583 | Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex |
| Q56362064 | Malaria Vaccines: Recent Advances and New Horizons |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q92449403 | Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ) |
| Q61451259 | Saponins from and : Particular Chemical Characteristics and Biological Activities |
| Q49829267 | The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases |
Search more.